

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Application Number		10714195	
	Filing Date		2003-11-14	
	First Named Inventor	Baker, Joffre B.		
	Art Unit	1634		
	Examiner Name	SHAW, AMANDA MARIE		
Attorney Docket Number		GHDX-005		

U.S. PATENTS						Remove
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button.

Add

U.S. PATENT APPLICATION PUBLICATIONS						Remove
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Published Application citation information please click the Add button.

Add

FOREIGN PATENT DOCUMENTS							Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ² j	Kind Code ⁴	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines where Relevant Passages or Relevant Figures Appear	T ⁵
	1							<input type="checkbox"/>

If you wish to add additional Foreign Patent Document citation information please click the Add button.

Add

NON-PATENT LITERATURE DOCUMENTS		Remove	
Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T ⁵

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Not for submission under 37 CFR 1.99)

Application Number	10714195
Filing Date	2003-11-14
First Named Inventor	Baker, Joffre B.
Art Unit	1634
Examiner Name	SHAW, AMANDA MARIE
Attorney Docket Number	GHDX-005

1	Airenne et al. Structure of the human laminin $\gamma 2$ chain gene (LAMC2): alternative splicing with different tissue distribution of two transcripts. 1996, Genomics 32:54.	<input type="checkbox"/>
2	Albanell et al. Activated extracellular signal-regulated kinases: association with epidermal growth factor receptor/transforming growth factor alpha expression in head and neck squamous carcinoma and inhibition by anti-epidermal growth factor receptor treatments. 2001, Cancer Research 61:6500-6510.	<input type="checkbox"/>
3	Baselga. Why the epidermal growth factor receptor? the rationale for cancer therapy. 2002, The Oncologist, suppl 4, pp. 2-8.	<input type="checkbox"/>
4	Ciardiello and Tortora, "A Novel Approach in the Treatment of Cancer: Targeting the Epidermal Growth Factor Receptor," 2001, Clin. Cancer Res. 7:2958-2970.	<input type="checkbox"/>
5	Tewes et al., "Results of a Phase I Trial of the Humanized Anti Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody EMD 72000 in Patients With EGFR Expressing Solid Tumors," Proc. Am. Soc. Clin. Oncol. Abstract 378 (2002)	<input type="checkbox"/>

If you wish to add additional non-patent literature document citation information please click the Add button

EXAMINER SIGNATURE

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.